{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:32:40Z","timestamp":1794331960305,"version":"4.9.0"},"reference-count":142,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","seminarsinnephrology.org","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.semnephrol.2018.02.003","type":"journal-article","created":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T18:27:05Z","timestamp":1525890425000},"page":"217-232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["Cardiovascular Disease and Diabetic Kidney Disease"],"prefix":"10.1016","volume":"38","author":[{"given":"Muhammad","family":"Maqbool","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin A.M.","family":"Jandeleit-Dahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2018.02.003_bib1","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1008862","article-title":"Diabetes mellitus, fasting glucose, and risk of cause-specific death","volume":"364","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib2","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2337\/diacare.20.5.704","article-title":"The impact of diabetes on survival among patients with first myocardial infarction","volume":"20","author":"Chun","year":"1997","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib4","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1161\/01.CIR.0000116389.61864.DE","article-title":"Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction","volume":"109","author":"Lee","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1053\/j.ackd.2014.03.003","article-title":"Cardiovascular complications of diabetic kidney disease. advances in chronic kidney disease","volume":"21","author":"P\u00e1lsson","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib6","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.2337\/db08-1543","article-title":"The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes","volume":"58","author":"Groop","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.diabres.2017.03.024","article-title":"IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040","volume":"128","author":"Ogurtsova","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib8","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib9","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/S0140-6736(12)62134-5","article-title":"GBD 2010: a multi-investigator collaboration for global comparative descriptive epidemiology","volume":"380","author":"Murray","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib10","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s00125-013-2966-1","article-title":"Survival in dialysis patients is different between patients with diabetes as primary renal disease and patients with diabetes as a co-morbid condition","volume":"56","author":"Schroijen","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib11","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1007\/s00125-010-1860-3","article-title":"In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study","volume":"53","author":"Orchard","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib12","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib13","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1681\/ASN.2013070754","article-title":"Association of body mass index with outcomes in patients with CKD","volume":"25","author":"Lu","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib14","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/ajcn\/83.2.202","article-title":"Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients","volume":"83","author":"Kalantar-Zadeh","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib15","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1053\/j.ajkd.2007.02.277","article-title":"Paradoxical association between body mass index and mortality in men with CKD not yet on dialysis","volume":"49","author":"Kovesdy","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.aogh.2013.12.007","article-title":"Cardiovascular pathophysiology in chronic kidney disease: opportunities to transition from disease to health","volume":"80","author":"Tomey","year":"2014","journal-title":"Ann Glob Health"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib17","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1089\/ars.2016.6664","article-title":"Diabetes and kidney disease: role of oxidative stress","volume":"25","author":"Jha","year":"2016","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1477-9560-3-3","article-title":"A hypothesis-generating study to evaluate platelet activity in diabetics with chronic kidney disease","volume":"3","author":"Brophy","year":"2005","journal-title":"Thromb J"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/ndt\/gfi075","article-title":"Left ventricular function in patients with chronic kidney disease evaluated by colour tissue Doppler velocity imaging","volume":"21","author":"Hayashi","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib20","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ahj.2010.03.027","article-title":"Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC)","volume":"159","author":"Soliman","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib21","doi-asserted-by":"crossref","first-page":"e0191155","DOI":"10.1371\/journal.pone.0191155","article-title":"Stroke risk and outcomes in patients with chronic kidney disease or end-stage renal disease: two nationwide studies","volume":"13","author":"Cherng","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1900\/RDS.2013.10.88","article-title":"Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients","volume":"10","author":"Chen","year":"2013","journal-title":"Rev Diabet Stud"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib23","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1111\/j.1523-1755.2005.09916.x","article-title":"Dyslipidemia and the progression of renal disease in chronic renal failure patients","volume":"68","author":"Cases","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11892-015-0611-8","article-title":"The evolving understanding of the contribution of lipid metabolism to diabetic kidney disease","volume":"15","author":"Stadler","year":"2015","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib25","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1046\/j.1523-1755.1999.07109.x","article-title":"Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy","volume":"71","author":"Jandeleit-Dahm","year":"1999","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1900\/RDS.2004.1.175","article-title":"Differential postprandial lipoprotein responses in type 2 diabetic men with and without clinical evidence of a former myocardial infarction","volume":"1","author":"Carstensen","year":"2004","journal-title":"Rev Diabet Stud"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib27","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.5551\/jat1994.2.Supplement1_S34","article-title":"Postprandial lipoprotein metabolism in diabetes mellitus and obesity","volume":"2","author":"Lewis","year":"1995","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1567-5688(15)50004-4","article-title":"Alterations of intestinal lipoprotein metabolism in diabetes mellitus and metabolic syndrome","volume":"17","author":"Arca","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib29","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00041552-200103000-00007","article-title":"Dyslipidemia and renal disease: pathogenesis and clinical consequences","volume":"10","author":"Wanner","year":"2001","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib30","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1525-139X.2009.00661.x","article-title":"Causes of dysregulation of lipid metabolism in chronic renal failure","volume":"22","author":"Vaziri","year":"2009","journal-title":"Semin Dial"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib31","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1053\/ajkd.2001.27384","article-title":"Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease","volume":"38","author":"Quaschning","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib32","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.arcmed.2015.05.009","article-title":"Residual cardiovascular risk in chronic kidney disease: role of high-density lipoprotein","volume":"46","author":"Kon","year":"2015","journal-title":"Arch Med Res"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib33","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s00726-010-0772-3","article-title":"Lipid glycation and protein glycation in diabetes and atherosclerosis","volume":"42","author":"Miyazawa","year":"2012","journal-title":"Amino Acids"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib34","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1053\/j.jrn.2008.10.011","article-title":"Lipid and lipoprotein metabolism in chronic kidney disease","volume":"19","author":"Kaysen","year":"2009","journal-title":"J Ren Nutr"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0272-6386(96)90026-8","article-title":"Lipoprotein(a) in renal disease","volume":"27","author":"Kronenberg","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib36","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/0735-1097(92)90520-W","article-title":"Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease","volume":"19","author":"Genest","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib37","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib38","doi-asserted-by":"crossref","first-page":"12633","DOI":"10.1074\/jbc.275.17.12633","article-title":"Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species","volume":"275","author":"Cominacini","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib39","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1046\/j.1523-1755.2001.00752.x","article-title":"Oxidative modification of low-density lipoproteins and the outcome of renal allografts at 1 and a half years","volume":"59","author":"Bosmans","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/jina.jina_1_17","article-title":"Association of lipid abnormalities and oxidative stress with diabetic nephropathy","volume":"4","author":"Kachhawa","year":"2017","journal-title":"J Integr Nephrol Androl"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib41","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0272-6386(12)70171-3","article-title":"Cellular mechanisms of lipid injury in the glomerulus","volume":"22","author":"Schlondorff","year":"1993","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib42","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2337\/dc12-s004","article-title":"Executive summary: standards of medical care in diabetes\u20132012","volume":"35","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib43","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.2337\/dc18-S009","article-title":"9. Cardiovascular disease and risk management: standards of medical care in diabetes\u20132018","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib44","article-title":"HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis","author":"Palmer","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib45","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib46","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib47","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/nep.12320","article-title":"KHA-CARI commentary on the KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease","volume":"19","author":"Palmer","year":"2014","journal-title":"Nephrology"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib48","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib49","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib50","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.amjcard.2004.08.076","article-title":"Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin","volume":"95","author":"Jones","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib51","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12933-017-0602-y","article-title":"Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia","volume":"16","author":"Fruchart","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib52","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib53","doi-asserted-by":"crossref","first-page":"470","DOI":"10.4065\/83.4.470","article-title":"Effects of niacin on glucose control in patients with dyslipidemia","volume":"83","author":"Goldberg","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib54","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1053\/j.ajkd.2014.11.033","article-title":"Niacin and progression of CKD","volume":"65","author":"Streja","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib55","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1161\/STROKEAHA.113.001529","article-title":"Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL\/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial","volume":"44","author":"Teo","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib56","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2165\/00003495-198019030-00001","article-title":"Colestipol: a review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolaemia","volume":"19","author":"Heel","year":"1980","journal-title":"Drugs"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib57","first-page":"237","article-title":"Bile acid sequestrants: their use in combination with other lipid-lowering agents","volume":"2","author":"Mandeville","year":"1999","journal-title":"IDrugs"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib58","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","article-title":"Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials","volume":"13","author":"Zhang","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib59","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1161\/JAHA.116.005367","article-title":"Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia","volume":"6","author":"Toth","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib60","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S2213-8587(16)00003-6","article-title":"Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data","volume":"4","author":"Sattar","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib61","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib62","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s11255-017-1505-2","article-title":"PCSK9 in chronic kidney disease","volume":"49","author":"Pavlakou","year":"2017","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib63","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/0140-6736(90)91908-S","article-title":"Blood pressure and coronary heart disease","volume":"336","author":"Collins","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib64","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38","volume":"317","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib65","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update","volume":"60","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib66","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib67","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1001\/archinternmed.2012.3147","article-title":"Intensive and standard blood pressure targets in patients with type 2 diabetes mellitus: systematic review and meta-analysis","volume":"172","author":"McBrien","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib68","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib69","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib70","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib71","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"Patel","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib72","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1161\/HYPERTENSIONAHA.115.05204","article-title":"AT2R agonist, compound 21, is reno-protective against type 1 diabetic nephropathy","volume":"65","author":"Koulis","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib73","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1161\/CIRCRESAHA.110.219279","article-title":"Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse","volume":"107","author":"Thomas","year":"2010","journal-title":"Circ Res"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib74","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.2337\/db07-1212","article-title":"ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes","volume":"57","author":"Tikellis","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib75","doi-asserted-by":"crossref","first-page":"IV6","DOI":"10.1002\/clc.4960141802","article-title":"Control of blood pressure by the renin-angiotensin-aldosterone system","volume":"14","author":"Hall","year":"1991","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib76","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1464-5491.1988.tb01062.x","article-title":"Exchangeable sodium in diabetes","volume":"5","author":"Ferriss","year":"1988","journal-title":"Diabet Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib77","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2337\/diacare.14.3.220","article-title":"Central role of sodium in hypertension in diabetic subjects","volume":"14","author":"Weidmann","year":"1991","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib78","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2337\/diacare.24.1.111","article-title":"Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients","volume":"24","author":"Imanishi","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib79","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0140-6736(12)60987-8","article-title":"Diabetes and hypertension: the bad companions","volume":"380","author":"Ferrannini","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib80","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1161\/01.HYP.31.5.1083","article-title":"Sodium induces hypertrophy of cultured myocardial myoblasts and vascular smooth muscle cells","volume":"31","author":"Gu","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib81","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/hr.2010.35","article-title":"The role of sympathetic nervous activity in renal injury and end-stage renal disease","volume":"33","author":"Masuo","year":"2010","journal-title":"Hypertens Res"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib82","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1081\/CEH-100001196","article-title":"Sympathetic nervous system, diabetes, and hypertension","volume":"23","author":"Perin","year":"2001","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib83","doi-asserted-by":"crossref","first-page":"304s","DOI":"10.1016\/S0895-7061(01)02236-1","article-title":"Sympathetic nervous system and insulin resistance: from obesity to diabetes","volume":"14","author":"Esler","year":"2001","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib84","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.2337\/db12-0138","article-title":"Neuroadrenergic dysfunction along the diabetes continuum: a comparative study in obese metabolic syndrome subjects","volume":"61","author":"Straznicky","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib85","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/FJC.0b013e3181d89670","article-title":"Vascular oxidative stress: the common link in hypertensive and diabetic vascular disease","volume":"55","author":"Cohen","year":"2010","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib86","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1161\/CIRCULATIONAHA.106.664250","article-title":"Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice","volume":"115","author":"Lewis","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib87","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.110.223545","article-title":"Oxidative stress and diabetic complications","volume":"107","author":"Giacco","year":"2010","journal-title":"Circ Res"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib88","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1172\/JCI118226","article-title":"Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype","volume":"96","author":"Heilig","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3317\/jraas.2002.001","article-title":"Role of endothelin in cardiovascular disease","volume":"3","author":"Agapitov","year":"2002","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib90","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/MNH.0b013e328335f91f","article-title":"Endothelin, hypertension and chronic kidney disease: new insights","volume":"19","author":"Kohan","year":"2010","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib91","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s00125-009-1540-3","article-title":"The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice","volume":"53","author":"Watson","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib92","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/13543784.2017.1325872","article-title":"Atrasentan for the treatment of diabetic nephropathy","volume":"26","author":"Egido","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib93","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1681\/ASN.2010080869","article-title":"Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy","volume":"22","author":"Kohan","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib94","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib95","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib96","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-134-5-200103060-00009","article-title":"Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data","volume":"134","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib97","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib98","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib99","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1111\/j.1523-1755.2005.00359.x","article-title":"Increased tubular organic ion clearance following chronic ACE inhibition in patients with type 1 diabetes","volume":"67","author":"Thomas","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib100","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","article-title":"Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect","volume":"106","author":"Viberti","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib101","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib102","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","article-title":"Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study","volume":"321","author":"Mogensen","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib103","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib104","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib105","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib106","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib107","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s00125-011-2325-z","article-title":"Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study","volume":"54","author":"Imai","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib108","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1291\/hypres.29.211","article-title":"Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection","volume":"29","author":"Sato","year":"2006","journal-title":"Hypertens Res"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib109","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2215\/CJN.04750908","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis","volume":"4","author":"Navaneethan","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib110","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib111","doi-asserted-by":"crossref","first-page":"707","DOI":"10.7326\/0003-4819-112-9-707","article-title":"Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus","volume":"112","author":"Bakris","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib112","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1524-6175.2004.4471.x","article-title":"Management of hypertensive chronic kidney disease: role of calcium channel blockers","volume":"7","author":"Toto","year":"2005","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib113","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib114","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2014.15688","article-title":"Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial","volume":"312","author":"Kosiborod","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib115","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib116","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib117","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib118","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib119","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib121","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.2337\/dc18-S006","article-title":"6. Glycemic targets: standards of medical care in diabetes-2018","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib122","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.2215\/CJN.00800209","article-title":"Frequency of hypoglycemia and its significance in chronic kidney disease","volume":"4","author":"Moen","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib123","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.2337\/dc13-0610","article-title":"HbA1c and risk of severe hypoglycemia in type 2 diabetes: the Diabetes and Aging Study","volume":"36","author":"Lipska","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib124","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib125","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib126","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib127","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib128","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib129","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib130","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2337\/dc14-2883","article-title":"Efficacy and safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): a randomized clinical trial","volume":"39","author":"Davies","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib131","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib132","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2147\/DDDT.S50773","article-title":"Update on developments with SGLT2 inhibitors in the management of type 2 diabetes","volume":"8","author":"Nauck","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib133","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib134","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib135","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib136","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S2213-8587(17)30182-1","article-title":"Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial","volume":"5","author":"Cherney","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib137","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib138","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib139","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib140","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S2213-8587(17)30258-9","article-title":"Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis","volume":"5","author":"Birkeland","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib141","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of sotagliflozin added to insulin in patients with type 1 diabetes","volume":"377","author":"Garg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.003_bib142","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S2213-8587(17)30308-X","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial","volume":"5","author":"Dandona","year":"2017","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027092951830024X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027092951830024X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T21:22:18Z","timestamp":1661203338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027092951830024X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":142,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S027092951830024X"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2018.02.003","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Disease and Diabetic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2018.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}